BioCentury | Jan 27, 2021
Management Tracks

Novartis’ chief digital officer stepping down; plus moves at Taysha, Roivant, Faze and more

...SVP, preclinical and translational science. Bond was most recently VP of cellular engineering at Kite Pharma. Karuna...
BioCentury | Sep 25, 2020
Finance

Human genetics leading the pull of investors into neuro

...chemogenetic platforms, and three others —Limbix, Karuna...
...Rules of the Road”). Both Limbix and Karuna...
...is focusing on depression in adolescents and Karuna...
BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

...a radiotherapeutic for the treatment of metastatic castrate-resistant prostate cancer. Karuna discontinues KarXT for pain Karuna...
...plus trospium chloride, xanomeline plus trospium chloride RXC006 Qinlock ripretinib (DCC-2618) fasinumab (MT-5547, REGN475, SAR164877) DBV Technologies S.A. Point Biopharma Inc. Karuna...
BioCentury | Jan 25, 2020
Company News

Jan. 24 Company Quick Takes: Tecentriq misses in bladder cancer; plus Gilead-CDC and PureTech

...Gilead (see "Gilead to Seek Pause in HIV PrEP Suit" ). PureTech sells $200M of Karuna...
...Karuna Therapeutics Inc. (NASDAQ:KRTX), leaving PureTech with a 20.4% stake in the biotech. In November, Karuna...
...emtricitabine/tenofovir Tecentriq (Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Gilead Sciences Inc. Roche Karuna Pharmaceuticals Inc. PureTech...
BioCentury | Jan 1, 2020
Financial News

Fourth quarter rally pushes biotech to strong finish

...Program” ). Data readouts also drove big stock gains during 4Q19 for companies such as Karuna...
...Inc. (NASDAQ:KRTX), Myovant Sciences Inc. (NASDAQ:MYOV), Axsome Therapeutics Inc. (NASDAQ:AXSM) and ChemoCentryx Inc. (NASDAQ:CCXI) (see “Karuna...
BioCentury | Nov 26, 2019
Clinical News

ChemoCentryx's valuation reaches nearly $1.8 billion after vasculitis readout

...stock move reflected continued investor enthusiasm for biotechs with strong clinical data in recent weeks. Karuna...
...more than doubled the next day after revealing Phase III data in prostate cancer (see "Karuna...
BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

...Since market close on Wednesday, Karuna, CRISPR Therapeutics, Molecular Therapeutics and OptiNose have raised an aggregate...
...Molecular Therapeutics and OptiNose have raised an aggregate of more than $600 million in follow-ons. Karuna...
...its close Monday when it proposed the offering. Karuna fell $29.58 (27%) to $79.37 Thursday. Karuna...
BioCentury | Nov 18, 2019
Clinical News

Karuna quintuples in value as schizophrenia combo clears Phase II bar

...avoiding the side effects that dogged a decades-old attempt to modulate the targets. Shares of Karuna...
...$29, just days after its June 2019 IPO. Data from the Phase II study showed Karuna's...
...to read out in mid-2020 (see "Karuna Looks Past Schizophrenia with Series B" ). Following Karuna's...
BioCentury | Sep 10, 2019
Financial News

Sept. 10 Financial Quick Takes: Qiming backs Insilico's B round; plus 10x Genomics, Aprea, Platelet, SGI-DNA, Dermavant, Karuna Labs

...not cite a reason for the move. Karuna Labs raises seed round Digital health company Karuna...
...joined by Anorak Ventures, the AET Fund, the Hustle Fund, Correlation Ventures and Dreamit Ventures. Karuna...
BioCentury | Aug 16, 2019
Finance

Chinese investment in U.S. biotechs to slow further

...Pharma Inc. and participated in a $68 million series B crossover round for neurology company Karuna...
...City, Calif. China Medical Systems Holding Ltd. (HKSE:867), Shenzen, China Inozyme Pharma Inc., Boston, Mass. Karuna...
Items per page:
1 - 10 of 29
BioCentury | Jan 27, 2021
Management Tracks

Novartis’ chief digital officer stepping down; plus moves at Taysha, Roivant, Faze and more

...SVP, preclinical and translational science. Bond was most recently VP of cellular engineering at Kite Pharma. Karuna...
BioCentury | Sep 25, 2020
Finance

Human genetics leading the pull of investors into neuro

...chemogenetic platforms, and three others —Limbix, Karuna...
...Rules of the Road”). Both Limbix and Karuna...
...is focusing on depression in adolescents and Karuna...
BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

...a radiotherapeutic for the treatment of metastatic castrate-resistant prostate cancer. Karuna discontinues KarXT for pain Karuna...
...plus trospium chloride, xanomeline plus trospium chloride RXC006 Qinlock ripretinib (DCC-2618) fasinumab (MT-5547, REGN475, SAR164877) DBV Technologies S.A. Point Biopharma Inc. Karuna...
BioCentury | Jan 25, 2020
Company News

Jan. 24 Company Quick Takes: Tecentriq misses in bladder cancer; plus Gilead-CDC and PureTech

...Gilead (see "Gilead to Seek Pause in HIV PrEP Suit" ). PureTech sells $200M of Karuna...
...Karuna Therapeutics Inc. (NASDAQ:KRTX), leaving PureTech with a 20.4% stake in the biotech. In November, Karuna...
...emtricitabine/tenofovir Tecentriq (Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Gilead Sciences Inc. Roche Karuna Pharmaceuticals Inc. PureTech...
BioCentury | Jan 1, 2020
Financial News

Fourth quarter rally pushes biotech to strong finish

...Program” ). Data readouts also drove big stock gains during 4Q19 for companies such as Karuna...
...Inc. (NASDAQ:KRTX), Myovant Sciences Inc. (NASDAQ:MYOV), Axsome Therapeutics Inc. (NASDAQ:AXSM) and ChemoCentryx Inc. (NASDAQ:CCXI) (see “Karuna...
BioCentury | Nov 26, 2019
Clinical News

ChemoCentryx's valuation reaches nearly $1.8 billion after vasculitis readout

...stock move reflected continued investor enthusiasm for biotechs with strong clinical data in recent weeks. Karuna...
...more than doubled the next day after revealing Phase III data in prostate cancer (see "Karuna...
BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

...Since market close on Wednesday, Karuna, CRISPR Therapeutics, Molecular Therapeutics and OptiNose have raised an aggregate...
...Molecular Therapeutics and OptiNose have raised an aggregate of more than $600 million in follow-ons. Karuna...
...its close Monday when it proposed the offering. Karuna fell $29.58 (27%) to $79.37 Thursday. Karuna...
BioCentury | Nov 18, 2019
Clinical News

Karuna quintuples in value as schizophrenia combo clears Phase II bar

...avoiding the side effects that dogged a decades-old attempt to modulate the targets. Shares of Karuna...
...$29, just days after its June 2019 IPO. Data from the Phase II study showed Karuna's...
...to read out in mid-2020 (see "Karuna Looks Past Schizophrenia with Series B" ). Following Karuna's...
BioCentury | Sep 10, 2019
Financial News

Sept. 10 Financial Quick Takes: Qiming backs Insilico's B round; plus 10x Genomics, Aprea, Platelet, SGI-DNA, Dermavant, Karuna Labs

...not cite a reason for the move. Karuna Labs raises seed round Digital health company Karuna...
...joined by Anorak Ventures, the AET Fund, the Hustle Fund, Correlation Ventures and Dreamit Ventures. Karuna...
BioCentury | Aug 16, 2019
Finance

Chinese investment in U.S. biotechs to slow further

...Pharma Inc. and participated in a $68 million series B crossover round for neurology company Karuna...
...City, Calif. China Medical Systems Holding Ltd. (HKSE:867), Shenzen, China Inozyme Pharma Inc., Boston, Mass. Karuna...
Items per page:
1 - 10 of 29